Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).
Small Cell Lung Cancer
DRUG: Anlotinib|DRUG: Placebo
Progress free survival (PFS), From randomizationï¼Œeach 42 days up to PD or death(up to 24 months)
Overall Survival (OS), From randomization until death (up to 24 months)|Objective Response Rate (ORR), each 42 days up to intolerance the toxicity or PD (up to 24 months)|Disease Control Rate (DCR), each 42 days up to intolerance the toxicity or PD (up to 24 months)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Until 30 day safety follow-up visit (up to 24 months)
To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).